Ascentage Pharma Group International (AAPG) Stock Price, News & Analysis

Company Overview

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr. Jackson Hu, Ascentage has built integrated discovery and translational research platforms based in Shanghai and Beijing. The company maintains a presence in North America with clinical and regulatory operations in the United States, and collaborates with research institutions and trial sites across Asia-Pacific, Europe and North America to advance its programs swiftly through Phase I and Phase II studies.

Ascentage’s clinical development portfolio spans indications such as acute myeloid leukemia, non-Hodgkin’s lymphoma, lung cancer and colorectal cancer, with biomarker‐driven strategies to optimize patient selection and response assessment. In addition to its oncology focus, the company is exploring novel applications in viral diseases by targeting host–virus interactions through modulation of apoptotic pathways.

In November 2020, Ascentage Pharma Group International completed its initial public offering on the NASDAQ Global Market under the ticker symbol “AAPG.” Led by Dr. Jackson Hu and a management team with deep expertise in oncology drug development, clinical operations and regulatory affairs, Ascentage aims to advance its pipeline toward regulatory submissions and commercialization to address significant unmet medical needs globally.

Key Stats

• Today's Range: $20.82 to $22.58
• 50-Day Range: $18.56 to $27.69
• 52-Week Range: $18.56 to $48.45
• Volume: 8,252 shs
• Average Volume: 6,045 shs
• Market Capitalization: $1.96 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.67
• Consensus Rating: Buy

Ascentage Pharma Group International Stock Analysis - MarketRank™

Ascentage Pharma Group International scored higher than 83% of companies evaluated by MarketBeat, and ranked 99th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Buy

Consensus Rating

Ascentage Pharma Group International has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 2 strong buy ratings, 6 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Ascentage Pharma Group International has a consensus price target of $46.67, representing about 122.1% upside from its current price of $21.01.

Amount of Analyst Coverage

Ascentage Pharma Group International has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ascentage Pharma Group International are expected to grow in the coming year, from ($1.09) to ($0.39) per share.

Price to Book Value per Share Ratio

Ascentage Pharma Group International has a P/B Ratio of 10.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Ascentage Pharma Group International has been sold short.

Short Interest Ratio / Days to Cover

Ascentage Pharma Group International has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ascentage Pharma Group International has recently decreased by 97.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ascentage Pharma Group International does not currently pay a dividend.

Dividend Growth

Ascentage Pharma Group International does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: -0.18

News Sentiment

Ascentage Pharma Group International has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Ascentage Pharma Group International this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for AAPG on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Ascentage Pharma Group International to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ascentage Pharma Group International insiders have not sold or bought any company stock.

Percentage Held by Institutions

Ascentage Pharma Group International has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 3/25/2026
• Today: 5/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AAPG
• Previous Symbol: NASDAQ:AAPG
• CIK: 2023311
• Web: N/A
• Phone: 86 512 8555 7777
• Fax: N/A
• Employees: 600
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Ascentage Pharma Group International: $46.67
• High Price Target: $51.00
• Low Price Target: $40.00
• Potential Upside/Downside: +122.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.57
• Current Ratio: 1.79
• Quick Ratio: 1.77

Sales & Book Value

• Annual Sales: $82.10 million
• Price / Sales: 23.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.04 per share
• Price / Book: 10.30

Miscellaneous

• Outstanding Shares: 93,330,000
• Free Float: N/A
• Market Cap: $1.96 billion
• Optionable: N/A
• Beta: 0.19